Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response
Name
Jacks PMC Genetically engineered (same as other).pdf
Size
1.01 MB
Format
Adobe PDF
Checksum (MD5)
8817fcd2ca5bb2f15858c3b6b7382e45
Author(s)
DuPage, Michel J.
Jacks, Tyler E.
Date Issued
April 2013
Journal
Current Opinion in Immunology
Publisher
Elsevier
Citation
DuPage, Michel, and Tyler Jacks. “Genetically Engineered Mouse Models of Cancer Reveal New Insights About the Antitumor Immune Response.” Current Opinion in Immunology 25, 2 (April 2013): 192–199
Version
Author's final manuscript
Abstract
Cancer is a complex disease that can originate in virtually all the tissues of the body, and tumors progress through many different stages during their development. While genetic mutations in the emerging cancer cells drive this disease, it has become increasingly clear that cancer development is strongly influenced by the surrounding microenvironment. Cells of the immune system are critical components of this extrinsic network of cancer regulators, contributing significantly to the microenvironment of most cancers and either promoting or inhibiting the initiation and progression of this disease. Genetically engineered mouse (GEM) mouse models of spontaneous cancer are starting to shape our understanding of how antitumor T cells may act to prevent or inhibit cancer progression in some settings and not others. Lessons learned from investigating spontaneous mouse cancer models have important implications for directing clinical efforts that attempt to direct a cancer patient's immune system to eradicate their disease.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.coi.2013.02.005
